Venetoclax and Lintuzumab-Ac225 in AML Patients

NCT03867682 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
Relapsed Adult AML

Interventions

BIOLOGICAL: Lintuzumab-Ac225
DRUG: Venetoclax
DRUG: Spironolactone

Sponsor

Actinium Pharmaceuticals